Riccardo Lacchini

Prof. Dr. Riccardo Lacchini

Ribeirao Preto College of Nursing – University of Sao Paulo, São Paulo 14040-902, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Open access
PDF file
GOGustavo H. Oliveira-Paula
Gustavo H. Oliveira-Paula
SPSherliane C. Pereira
Sherliane C. Pereira
JTJose E. Tanus-Santos
Jose E. Tanus-Santos
Riccardo LacchiniRiccardo Lacchini
Riccardo Lacchini
Hypertension is a multifactorial disease that affects approximately one billion subjects worldwide and is a major risk factor associated with cardiovascular events, including coronary heart disease and cerebrovascular accidents. Therefore, adequate blood pressure control is important to prevent these events, reducing premature mortality and disability. However, only one third of patients have the effective control of blood pressure, despite several classes of antihypertensive drugs available. These disappointing outcomes may be at least in part explained by interpatient variability in drug response due to genetic polymorphisms. To address the effects of genetic polymorphisms on blood pressure responses to the antihypertensive drug classes, studies have applied candidate genes and genome wide approaches. More recently, a third approach that considers gene-gene interactions has also been applied in hypertension pharmacogenomics. In this article, we carried out a comprehensive review of recent findings on the pharmacogenomics of antihypertensive drugs, including diuretics, β-blockers, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, and calcium channel blockers. We also discuss the limitations and inconsistences that have been found in hypertension pharmacogenomics and the challenges to implement this valuable approach in clinical practice.

31 October 2023 in Healthcare
Verified
Journal Article
Open access
PDF file
Edilaine Cristina da Silva Gherardi-DonatoEdilaine Cristina da Silva Gherardi-Donato
Edilaine Cristina da Silva Gherardi-Donato
LGLarissa Gimenez
Larissa Gimenez
MFMaria Neyrian de Fátima Fernandes
Maria Neyrian de Fátima Fernandes
Riccardo LacchiniRiccardo Lacchini
Riccardo Lacchini
Elton Brás Camargo JúniorElton Brás Camargo Júnior
Elton Brás Camargo Júnior
EREmilene Reisdorfer
Emilene Reisdorfer
Background: Anxiety and stress are common mental health conditions reported by university workers. Practices of mindfulness represent one promising approach as an effective and feasible means to reduce stress, improve mental health and promote well-being; however, there are no clinical trials that have combined long-term stress biomarkers (hair cortisol) and psychometric assessments in a sample of university workers. Objective: This study investigated the effectiveness of a mindfulness-based program on long-term stress, by measuring hair cortisol concentration and perceived stress and anxiety among workers who were undergoing high levels of stress. Method: We conducted a randomized clinical trial at work among the employees of a public university. We compared a group that received the eight-week mindfulness intervention with the wait list group who received no intervention. Results: A total of 30 participants were included in the study, with n = 15 subjects in the intervention group and n = 15 in the control group. Hair cortisol, perceived stress and anxiety significantly reduced after the intervention compared to the control group, which had no appreciable decline in the measured variables. Conclusion: This clinical trial showed the effectiveness of a mindfulness program on mental health psychometric measures (perceived stress and anxiety) and on a long-term stress biomarker (hair cortisol). It can be concluded that an eight-week mindfulness program could be implemented as an effective strategy to reduce stress biomarkers (hair cortisol) as well as perceived stress and anxiety, improving the mental health of university workers.

1 March 2014 in Journal of the American Society of Hypertension
Verified
Journal Article
Closed access
VFVanessa Fontana
Vanessa Fontana
AFAna Paula Cabral de Faria
Ana Paula Cabral de Faria
NBNatália Ruggeri Barbaro
Natália Ruggeri Barbaro
ASAndréa Rodrigues Sabbatini
Andréa Rodrigues Sabbatini
RMRodrigo Modolo
Rodrigo Modolo
HMHeitor Moreno
Heitor Moreno

23 June 2013 in Alcohol and Alcoholism
Verified
Journal Article
Open access
PDF file
LLLetícia N. Leite
Letícia N. Leite
Riccardo LacchiniRiccardo Lacchini
Riccardo Lacchini
ECEvelin Capellari Carnio
Evelin Capellari Carnio
RQRegina H. Queiroz
Regina H. Queiroz
Jose Tanus-SantosJose Tanus-Santos
Jose Tanus-Santos
Carlos R. TirapelliCarlos R. Tirapelli
Carlos R. Tirapelli
Aims: We investigated the effects of chronic ethanol consumption on the cavernosal smooth muscle (CSM) reactivity to endothelin-1 (ET-1) and the expression of ET system components in this tissue. Methods: Male Wistar rats were treated with heavy dose of ethanol (20% v/v) for 6 weeks. Reactivity experiments were performed in the isolated rat CSM. Plasma and CSM nitrate generation and also superoxide anion generation in rat CSM were measured by chemiluminescence. Protein and mRNA levels of pre-pro-ET-1, endothelin-converting enzyme-1 (ECE-1), ETA and ETB receptors, eNOS, nNOS and iNOS were assessed by western immunoblotting and quantitative real-time polymerase chain reaction, respectively. Results: Chronic ethanol consumption increased plasma ET-1 levels and the contractile response induced by this peptide in the isolated CSM. The relaxation induced by acetylcholine, but not IRL1620, a selective ETB receptor agonist, was reduced in CSM from ethanol-treated rats. BQ123, a selective ETA receptor antagonist, produced a rightward displacement of the ET-1 concentration–response curves in CSM from control, but not ethanol-treated rats. Reduced levels of nitrate were found in the plasma and CSM from ethanol-treated rats. Ethanol consumption increased superoxide anion generation in the rat CSM. The mRNA levels of pre-pro-ET-1, ECE-1, ETA and ETB receptors, eNOS, nNOS and iNOS were not altered by ethanol consumption. Protein levels of ET-1, ETA receptor and iNOS were higher in the CSM from rats chronically treated with ethanol. Conclusion: The major findings of the present study are that heavy ethanol consumption increases plasma ET-1 levels and the contraction induced by the peptide in the CSM. Increased CSM reactivity to ET-1 and altered protein levels of ET-1 and ETA receptors could play a role in the pathogenesis of erectile dysfunction associated with chronic ethanol consumption.

29 August 2020 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
Cezar KayzukaCezar Kayzuka
Cezar Kayzuka
GOGustavo Henrique Oliveira-Paula
Gustavo Henrique Oliveira-Paula
VPVitória Carolina Rondon Pereira
Vitória Carolina Rondon Pereira
Riccardo LacchiniRiccardo Lacchini
Riccardo Lacchini
Nitric Oxide (NO) is a molecule with multiple functions. Several drugs involve the modulation of NO levels in their mechanism of action. NO is mainly produced in vessels by endothelial NO synthase,...

31 October 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
IMItiana Castro Menezes-Pazini
Itiana Castro Menezes-Pazini
CBCristiane von Werne Baes
Cristiane von Werne Baes
FFFernanda Viana Fígaro-Drumond
Fernanda Viana Fígaro-Drumond
BMBrisa Burgos Dias Macedo
Brisa Burgos Dias Macedo
ABAna Carolina Bueno
Ana Carolina Bueno
Mario F. JuruenaMario F. Juruena
Mario F. Juruena
Few studies have assessed biomarkers for the differentiation of major depressive disorder (MDD) and bipolar disorder (BD). However, some elements of depression such as hormones and receptors of the renin–angiotensin–adrenal system (RAAS), the hypothalamus–pituitary–adrenal (HPA) axis, and history of early-life stress (ELS) could be considered for differential diagnosis. Therefore, this study aimed to assess aldosterone and cortisol levels, MR and GR gene polymorphisms, and ELS as potential biomarkers for differentiating MDD and BD. This study presents a case–control design. Groups comprised samples for genetic, cortisol, and aldosterone analysis: healthy control (HC; n = 113/97/103), MDD (n = 78/69/67) and BD (n = 82/68/65) subjects. Furthermore, all subjects were assessed for diagnostic screening, the severity of depression, and history of ELS by applying MINI-PLUS, GRID-HDRS, and CTQ, respectively. In addition, genotype and allelic frequencies of GR (N363S, R22/23K and BclI) and MR (MI180V and -2G/C) polymorphisms were evaluated via PCR. Our findings demonstrate that basal aldosterone levels may be a biomarker for differentiating BD and MDD. Furthermore, ELS affects the HPA axis in BD, cortisol may be considered a biomarker for distinguishing BD and MDD, but only in the absence of ELS, and, finally, history of ELS and MR-2G/C variant alleles are factors that contribute to the severity of depressive symptoms in MDD and BD.